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A Pharmacokinetically Based Risk Factor for Prediction of
Early Creatinine Increase After Percutaneous Coronary Intervention
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Objectives This study sought to validate a pharmacokinetically derived measure of the risk of an early increase in serum
creatinine after percutaneous coronary intervention (PCI).
Background The ratio of the volume of contrast media to the creatinine clearance (V/CrCl) has been shown to correlate with
the area under the curve of contrast media concentration over time.
Methods We calculated V/CrCl in 3,179 consecutive patients undergoing PCI. An increase in serum creatinine of 0.5
mg/dl by 24 to 48 h was considered abnormal. Receiver-operator characteristic methods were used to identify
the optimal sensitivity and specificity for the observed range of V/CrCl. The predictive value of V/CrCl for the risk
of an early increase in creatinine was assessed using multivariable logistic regression.
Results The overall incidence of an abnormal, early increase in creatinine was 1.5%. The mean and median values of
V/CrCl for patients with (mean 5.2  4.4, median 4.3, interquartile range 2.7 to 6.0) and without (mean 3.0 
2.0, median 2.5, interquartile range 1.7 to 3.8) an early creatinine increase were each significantly (p  0.001)
different between groups. Furthermore, there was a significant association between V/CrCl and an early increase
in creatinine (overall and trend, p  0.001). The receiver-operator characteristic curve analysis indicated that a
V/CrCl ratio of 3.7 was a fair discriminator for the early creatinine increase (C-statistic 0.69). After adjusting for
other known predictors of post-PCI creatinine increase, V/CrCl 3.7 remained significantly associated with an
early abnormal increase in serum creatinine (odds ratio 3.84; 95% confidence interval 2.0 to 7.3, p  0.001).
Conclusions A V/CrCl ratio 3.7 was a significant and independent predictor of an early abnormal increase in serum creati-
nine after PCI in this unselected patient population. (J Am Coll Cardiol 2007;50:584–90) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.058b
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aadiographic contrast media-associated nephrotoxicity
CAN) is responsible for approximately 11% of all iatro-
enic renal insufficiency and is the third most common
ause of hospital-acquired renal failure (1). Contrast media-
ssociated nephrotoxicity is traditionally defined as an in-
rease in serum creatinine of either 0.5 mg/dl or 25% from
rom the *University of New Mexico School of Medicine, Albuquerque, New
exico; †University of Pittsburgh, Pittsburgh, Pennsylvania; ‡University of Penn-
ylvania School of Medicine, Philadelphia, Pennsylvania; §Lenox Hill Heart and
ascular Institute, New York, New York; and the Mayo Clinic, Rochester,
innesota. This study was supported in part by grant HL 33292-14 from the
ational Heart, Lung, and Blood Institute, Bethesda, Maryland, and the Robert S.
linn Endowment for Cardiovascular Medicine (University of New Mexico School of
edicine).(
Manuscript received January 29, 2007; revised manuscript received March 1, 2007,
ccepted March 28, 2007.aseline within 72 h of exposure (2,3). The association of
he above-specified magnitude and time course of serum
reatinine increase with short- and long-term adverse clin-
cal outcomes is well established (4–6). Given that the
ajority of patients currently undergoing invasive cardio-
ascular procedures are either outpatients or are likely to be
ischarged within 24 h after the procedure (7), assessment
f changes in serum creatinine beyond 24 h often is
roblematic. Therefore, a practical means of predicting an
arly postprocedural increase in creatinine would be of
linical benefit. Although underlying renal insufficiency and
iabetes mellitus are known risk factors for the development
f CAN (8,9), the precise role of the volume of contrast
dministered has yet to be established (9–14).
In pharmacokinetic terms, systemic exposure to a drug
and, therefore, its safety and efficacy profile) is best quan-
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August 14, 2007:584–90 Contrast Nephropathyified by the area under the drug’s blood concentration
ersus time curve (15). Recently, the derivation and valida-
ion of V/CrCl as a surrogate for the area under the curve
as been reported in normal volunteers (16). We hypothe-
ized that this index would be useful in the prediction of an
bnormal increase in post-percutaneous coronary interven-
ion (PCI) creatinine and that this index would show better
redictive performance over considerations of volume or
nderlying renal function alone (6,8,9,11,12). We tested
his hypothesis prospectively in an unselected population of
atients undergoing PCI.
ethods
heoretical background. Systemic exposure to a drug is
est assessed by quantifying the area under the blood
oncentration versus time curve. Contrast media are distrib-
ted and eliminated consistent with a linear model (17,18).
ystemic clearance of a drug is equal to the ratio of the
ollowing time-dependent variables: the rate of elimination,
X/dt(t), and the blood drug concentration, C(t). Thus,
Clearance
dX ⁄ dt(t)
C(t)
[1]
ntegrating numerator and denominator in Equation 1
ields:
Clearance
 (dX ⁄ dt)dt
C(t)dt

Total Dose
AUC
[2]
earranging Equation 2 yields:
AUC
Total Dose
Systemic Clearance
[3]
herefore, systemic exposure (area under the curve) is
irectly related to dose and inversely related to systemic
learance. For contrast media exposure, the volume of
ontrast injected is equal to the total dose. Because contrast
edia are renally excreted in an unmetabolized state (19),
heir systemic clearance can be approximated by the creat-
nine clearance. Thus, the area under the blood concentra-
ion versus time curve can be approximated by the total
olume of contrast given divided by creatinine clearance
CrCl):
AUC
Volume
CrCl
[4]
atient population. The present study population is com-
osed of consecutive patients enrolled in the National
eart, Lung, and Blood Institute Dynamic Registry under-
oing PCI in recruitment waves 4 (February 2004 to May
004) and 5 (February 2006 to August 2006). The Dynamic oegistry is a multicenter registry
25 clinical centers in the U.S.
nd Canada) whose purpose,
tructure, and function have been
reviously reported (20,21). Data
ollected include patient history,
emographics, and procedural
etails including the total volume
f contrast administered and in-
ospital adverse events. In combined waves 4 and 5 (n 
,093), after excluding patients with no recorded contrast
olume (n  107), those on dialysis (n  125), those
ithout paired creatinine determinations (n  649), and
hose without recorded weight or age (n  33), data from
,179 patients were available for the present analysis. An
ncrease in creatinine from baseline of0.5 mg/dl after PCI
as considered abnormal. The volume (V) to creatinine
learance (CrCl) ratio, an estimate of contrast media area
nder the curve, was calculated by dividing the volume of
ontrast received by the patient’s CrCl. The CrCl was
stimated using the Cockcroft-Gault method (22): CrCl
ml/min)  140  age (years)  weight (kg)/72  serum
reatinine (mg/dl) { 0.85 for female subjects}.
tatistical analysis. Crude incidence rates for in-hospital
dverse events and abnormal post-PCI creatinine increases
ere calculated. Continuous explanatory variables were
ategorized into either accepted cut points (e.g., decades for
ge) or into tertiles (e.g., contrast volume). Odds ratios and
5% confidence intervals were calculated using logistic
egression. Additionally, continuous variables are summa-
ized as mean SD or medians and interquartile ranges and
ompared using the Wilcoxon rank sum test. Receiver-
perator characteristics analysis was used to determine the
ptimal cut point for V/CrCl in this population using SPSS
version 14.0, SPSS Inc., Chicago, Illinois). Logistic regres-
ion was used to model the association between the V/CrCl
ut point (identified by the receiver-operator characteristics
nalysis) and an abnormal increase in creatinine. Risk factors
ere initially screened for univariate association with an ab-
ormal increase in creatinine at p  0.20, and identified
ariables were then assessed in a forward stepwise manner
sing a p value criterion of0.05. The final model includes the
olume/clearance ratio and other important baseline character-
stics and is also adjusted for age and diabetes mellitus. The
oodness-of-fit assumption was assessed using the Hosmer-
emeshow method and satisfied when p  0.05. Statistical
ignificance for all comparisons was defined when p  0.05.
esults
he mean age for the entire population was 64  12 years;
he mean body mass index was 29.5  6.4 kg/m2; the mean
reatinine clearance was 86.9  38.2 ml/min; and the mean
stimated glomerular filtration rate (using the Modification
Abbreviations
and Acronyms
CAN  contrast media-
associated nephrotoxicity
CrCl  creatinine clearance
PCI  percutaneous
coronary interventionf Diet in Renal Disease method) was 74.8  25.1 ml/min.
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Contrast Nephropathy August 14, 2007:584–90Postprocedural creatinine values were available in 92.8%
f patients at 24 h and in an additional 6.8% from 24 h and
8 h. The overall incidence of an abnormal increase in
reatinine, as previously defined, was 1.5%.
As seen in Table 1, older patients (70 to 79 years and80
ears) were significantly more likely to develop an early
ncrease in creatinine compared with patients 60 years.
he mean age for those without an increase in creatinine
as 63.9  12 years and 69.9  12 years for those with a
reatinine increase (p  0.001). There was no association
etween this early increase in creatinine and gender. Pa-
ients with a creatinine increase were more likely to have a
ower body mass index (mean 27.5  4.8) compared with
Univariate Association of Patient Demographicsa E ly Abnormal Creatinine Increase After Per
Table 1 Univariate Association of Patient Dan Early Abnormal Creatinine Increa
Factor
Number of
Patients I
Age (yrs)
60 1,218
60–69 869
70–79 799
80 293
Body mass index (kg/m2)
25.0 695
25.0–29.9 1,219
30.0 1,259
Gender
Male 2,155
Female 1,024
Race
White 2,499
Black 521
Other 147
History of congestive heart failure
No 2,814
Yes 296
Congestive heart failure on admission
No 2,943
Yes 223
Chronic kidney disease
No 2,948
Yes 231
Peripheral vascular disease
No 2,912
Yes 267
Cerebrovascular disease
No 2,924
Yes 255
Pulmonary disease
No 2,921
Yes 258
Diabetes
No 2,113
Yes 1,061
Creatinine clearance (ml/min)
30 81
30–59 74560 2,353 0hose without an increase in creatinine (mean 29.5  6.4;
 0.02). Compared with white patients, black patients
ere 2.3 times more likely to develop an early increase in
reatinine. Patients with a history of concomitant disease,
e.g., congestive heart failure, chronic kidney disease [de-
ned historically in the Dynamic Registry], cerebrovascular
isease, or diabetes mellitus) all had a significant or near
ignificant higher risk of early creatinine increase. The mean
aseline creatinine in those patients with a history of
hronic kidney disease was significantly higher than those
ithout a history of chronic kidney disease (1.85  0.87 vs.
.05  0.28, respectively; p  0.001). Lower values for
rCl were associated with a higher risk for post-PCI
Cardiac Risk Factors Witheous Coronary Intervention
raphics and Cardiac Risk Factors With
fter Percutaneous Coronary Intervention
ce (%) Odds Ratio
95% Confidence
Interval p Value
.8 1.0 Reference —
.0 1.26 0.51–3.12 0.61
.0 2.47 1.11–5.47 0.03
.4 5.61 2.43–12.92 0.001
.9 1.0 Reference —
.0 1.05 0.53–2.08 0.88
.9 0.46 0.21–1.04 0.06
.5 1.0 Reference —
.6 1.05 0.57–1.93 0.87
.2 1.0 Reference —
.9 2.37 1.27–4.43 0.007
.4 1.10 0.26–4.66 0.89
.2 1.0 Reference —
.7 4.06 2.15–7.66 0.001
.3 1.0 Reference —
.5 3.59 1.76–7.30 0.001
.2 1.0 Reference —
.2 4.43 2.27–8.64 0.001
.4 1.0 Reference —
.2 1.57 0.66–3.73 0.31
.4 1.0 Reference —
.1 2.33 1.08–5.04 0.03
.4 1.0 Reference —
.3 1.63 0.69–3.88 0.27
.2 1.0 Reference —
.1 1.70 0.96–3.01 0.07
.9 6.06 2.02–18.15 0.001
.2 3.88 2.13–7.07 0.001andcutan
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August 14, 2007:584–90 Contrast Nephropathyreatinine increase. The mean CrCl in patients with an early
ncrease in creatinine was significantly lower (67.6  41.5
l/min) compared with patients without an increase in
reatinine (87.2  38.1 ml/min; p  0.001) as was the
stimated glomerular filtration rate (69.5  42.9 ml/min vs.
4.9  24.7 ml/min; p  0.006).
Procedural characteristics are shown in Table 2. There
as no association between the total volume or type of
ontrast media (nonionic low osmolar, nonionic iso-
smolar, ionic high osmolar, ionic low osmolar) and an early
reatinine increase. The significant association between an
bnormal creatinine increase and periprocedural hydration
ikely reflects the use of the latter more often in subjects at
isk of CAN. There was a borderline significant difference
n the total volume of contrast administered to those with
255  124 ml) and without (224  112 ml; p  0.06) the
arly increase in creatinine.
As seen in Table 3, patients with an early creatinine
ncrease had lower rates of angiographic and procedural
uccess and a significantly higher incidence of postproce-
ural complications; specifically, bleeding requiring transfu-
ion, death, and death or myocardial infarction. The overall
ncidence of any major adverse clinical event (defined as
eath, myocardial infarction, or coronary bypass surgery)
nivariate Association of Procedural Characteristics With anarly Abnormal Creatinine Incr ase After PCI
Table 2 Univariate Association of Procedural Characteristics WEarly Abnormal Creatinine Increase After PCI
Factor Number of Patients Incid
Acute MI
No 2,180
Yes 999
Intravenous hydration before PCI
No 2,631
Yes 534
Contrast volume (ml)
169 1,049
170–249 1,036
249 1,094
Number of significant lesions (70%)
0/1 992
2 739
3 537
4 341
5 570
Number of lesions attempted
1 2,400
2 650
3 129
Stent used
No 165
Yes 3,014
Contrast media type*
Nonionic low osmolar 1,749
Nonionic iso-osmolar 943
Ionic high osmolar 67
Ionic low osmolar 304Patients given more than one type of contrast media have been excluded (n  11).
MI  myocardial infarction; PCI  percutaneous coronary intervention.as significantly higher in the patients with an early
bnormal creatinine increase.
The mean V/CrCl ratio was 3.0 2.0 in patients without
creatinine increase and 5.2  4.4 in patients with an
ncrease in creatinine (p  0.001), whereas the median
/CrCl ratios for those without and with CAN were 2.5
interquartile range 1.7 to 3.8) and 4.3 (interquartile range
.7 to 6.0), respectively (p  0.001). There was a significant
ssociation between higher V/CrCl ratio values and the risk
f an early increase in creatinine (Fig. 1). The distribution of
alues for V/CrCl in patients with and without an early,
bnormal increase in creatinine is shown in Figure 2.
Receiver-operator characteristic curve analysis showed
air discrimination between patients with and without an
arly increase in creatinine (C-statistic of 0.69) at a V/CrCl
atio of 3.7 (Fig. 3). At this value, the sensitivity and
pecificity for detection of an early, abnormal post-PCI
reatinine increase were 65% and 75%, respectively.
Univariate logistic regression indicated that V/CrCl was a
ighly significant predictor of an early abnormal creatinine
ncrease (odds ratio 5.06; 95% confidence interval 2.79 to
.20). Multivariable analysis indicated that a V/CrCl 3.7
as significantly and independently related to the risk of an
n
(%) Odds Ratio 95% Confidence Interval p Value
1.0 Reference —
1.57 0.88–2.80 0.13
1.0 Reference —
2.06 1.10–3.86 0.02
1.0 Reference —
1.67 0.78–3.55 0.18
1.67 0.79–3.52 0.18
1.0 Reference —
0.89 0.36–2.20 0.81
0.77 0.27–2.19 0.62
1.21 0.42–3.47 0.72
2.66 1.27–5.57 0.009
1.0 Reference —
1.68 0.89–3.18 0.11
1.82 0.55–6.03 0.33
1.68 0.59–4.72 0.33
1.0 Reference —
1.0 Reference —
1.14 0.60–2.17 0.68
n/a n/a n/a
1.67 0.72–3.87 0.23ith a
ence
1.3
2.0
1.6
2.6
1.0
1.7
1.7
1.2
1.1
0.9
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Contrast Nephropathy August 14, 2007:584–90arly abnormal increase in creatinine (Table 4). Notably, the
otal volume of contrast was not retained in the final model.
iscussion
n this report we show the predictive utility of the ratio of
he volume of contrast media administered to the estimated
reatinine clearance in assessing the risk of an abnormal
arly post-PCI increase in serum creatinine. Because
nivariate Association of In-Hospital Outcomes With an Earlybnormal Creatinine Increase After Percutan ous Coronary Interve
Table 3 Univariate Association of In-Hospital Outcomes With aAbnormal Creatinine Increase After Percutaneous Coro
Factor Number of Patients Inciden
Total angiographic success
No 144 5
Yes 3,029 1
Procedural success
No 98 10
Yes 3,075 1
Bleeding requiring transfusion
No 3,125 1
Yes 54 13
Death
No 3,153 1
Yes 26 26
Death or myocardial infarction
No 3,082 1
Yes 97 9
Stroke
No 3,167 1
Yes 10 10
MACE
No 3,063 1
Yes 116 7
ACE  major adverse clinical event.
Figure 1 Relationship Between V/CrCl
Ratio and Early Creatinine Increase
The association between ratio of the volume of contrast media to the creati-
nine clearance (V/CrCl) and the percentage of patients with an early abnormal
increase in creatinine after percutaneous coronary intervention (PCI) was highly
significant (p  0.001 overall and for trend)./CrCl corresponds closely to the area under the blood
ontrast media concentration versus time curve, this index
hould more closely predict the safety profile of contrast
edia, particularly with respect to the risk of CAN, than
he absolute volume of contrast alone.
The literature on the subject of CAN is extensive and has
een the subject of numerous recent comprehensive reviews
3,23–27). Several studies have sought to establish a rela-
ionship between the total volume of contrast media admin-
stered, baseline renal function, and risk of CAN after
ly
Intervention
Odds Ratio 95% Confidence Interval p Value
4.40 2.02–9.57 0.001
1.0 Reference —
9.08 4.38–18.81 0.001
1.0 Reference —
1.0 Reference —
11.20 4.78–26.26 0.001
1.0 Reference —
27.97 11.15–70.16 0.001
1.0 Reference —
7.98 3.75–16.98 0.001
1.0 Reference —
7.38 0.92–59.39 0.06
1.0 Reference —
6.52 3.08–13.82 0.001
Figure 2 Distribution of V/CrCl Ratio in Current Study
The distributions of ratio of the volume of contrast media to the creatinine
clearance (V/CrCl) values in patients with and without an early abnormal
increase in creatinine were significantly different (p  0.001). CAN  contrast
media-associated nephrotoxicity.ntion
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August 14, 2007:584–90 Contrast Nephropathyngiography. Contrast volume/CrCl was used in a retro-
pective analysis of 152 patients with chronic kidney disease
defined as a baseline creatinine2.0 mg/dl) and was found
o be predictive of CAN (defined as an increase in creatinine
f 1.0 mg/dl) at a cutoff value of 6.0 (28). This cutoff was
hen used prospectively in 250 consecutive patients (creati-
ine of 0.3 to 5.8 mg/dl) and found to have a sensitivity of
9% and specificity of 97% for predicting CAN (28). These
ata are not strictly comparable with those reported herein
ecause of differences in the number of patients studied, the
umber with chronic kidney disease, and the definition and
verall incidence of CAN.
A contrast volume limit of 5 ml/kg divided by serum
reatinine has been proposed as a way to predict CAN in
Figure 3 Receiver-Operator Characteristics Curve
Receiver-operator characteristics analysis indicated an optimum cutoff value for
ratio of the volume of contrast media to the creatinine clearance (V/CrCl) of
3.7 (*). The C-statistic was 0.69.
Multivariable Association Between an EarlyAbnormal Increa e in Creatinin Level After PCI
Table 4 Multivariable Association BetweenAbnormal Increase in Creatinine Le
Variable Od
Volume/CrCl ratio 3.7
Age 65 yrs
Black (vs. other races)
Attempted high-risk lesion without collaterals
Diabetes mellitus
History of congestive heart failure
Emergent PCI
Chronic kidney disease
Variables considered but not included in the final model: gender, heig
myocardial infarction, hypertension, dyslipidemia, smoking, vessel dis
myocardial infarction), cardiogenic shock, attempted lesion containing
vein graft, attempted lesion located in a bifurcation, attempted lesio
located in an ostial location, attempted lesion with calcium, number
history of peripheral vascular disease, stent use, history of cerebrovascular d
PCI  percutaneous coronary intervention; V/CrCl  volume of contrast matients receiving contrast media (29). This was validated in
15 patients with chronic kidney disease (Cr 1.8 mg/dl)
ndergoing angiography. Patients who received 5 ml/kg/
erum creatinine had a higher incidence of CAN. This
ormula was applied retrospectively in 16,592 patients un-
ergoing cardiac catheterization to determine its utility in
redicting the risk of postprocedural dialysis. Patients who
eceived a volume of contrast in excess of 5 ml/kg/serum
reatinine were 6-fold more likely to develop nephropathy
equiring dialysis (30).
In our study of 3,179 consecutive unselected patients under-
oing PCI, we found that a V/CrCl3.7 predicted the patient
t risk for an abnormal early postprocedural increase in creat-
nine. In contrast to the aforementioned studies, we included a
roader spectrum of patients and used a more practical crite-
ion for CAN—an early, abnormal increase in creatinine.
lthough the true incidence of the traditionally defined CAN
2,3) is likely underestimated in our study because of the failure
o obtain sufficient samples beyond 24 h, our results are
elevant to those patients for whom the detection of an early
ncrease in postprocedural creatinine may be meaningful (31).
uch evidence of renal vulnerability to the effects of contrast
edia are useful for risk stratification. Furthermore, real-world
linical practice often precludes observing the majority of
atients beyond 24 h. Despite the likely underestimation of the
ncidence of CAN without systematic 48- and 72-h sampling,
ur data regarding the value of V/CrCl as a predictor of an
arly postprocedural increase in creatinine remain valid. In this
ample we were also able to confirm the previously described
ssociation between an abnormal post-PCI creatinine increase and
dverse in-hospital outcomes (9) despite the overall low risk of the
resent population. Additional studies of the utility of this ratio in
opulations with more prevalent underlying kidney disease under-
oing angiography and/or PCI and with more extended creatinine
eterminations would be informative.
The relationship posited herein between contrast volume,
enal exposure, and the risk of CAN does not take into account
he many unpredictable hemodynamic and rheologic distur-
ances during PCI. Previous studies, as well as the present
V/CrCl Ratio
rly
fter PCI and V/CrCl Ratio
tio 95% Confidence Interval p Value
2.01–7.34 0.001
0.85–3.43 0.13
1.17–4.36 0.015
1.01–18.00 0.049
0.77–2.65 0.26
1.27–5.09 0.008
2.00–7.66 0.001
1.19–5.21 0.016
ight, body mass index, prior PCI, prior coronary bypass surgery, prior
ason for revascularization (i.e., stable angina, unstable angina, acute
bus, attempted totally occluded lesion, attempted lesion located in a
ying collateral vessels, attempted torturous lesion, attempted lesion
ficant lesions, number of lesions attempted, contrast media volume,and
an Ea
vel A
ds Ra
3.84
1.71
2.26
4.26
1.43
2.55
3.92
2.49
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Contrast Nephropathy August 14, 2007:584–90tudy, have identified numerous clinical, demographic, and
rocedural factors that are significantly associated with CAN
fter PCI (32,33). That V/CrCl remained independently
ssociated with the risk of an early postprocedural creatinine
ncrease after adjustment for these important confounders
Table 4) is supportive of our original hypothesis.
This study was not intended to examine the relationship
etween the type of contrast media and the risk of CAN.
he inability to identify an association between these
ariables is the result of a combination of factors: nonran-
om assignment of contrast media, operator bias in the
hoice of contrast media, and type II error attribuable to the
ow overall event rate.
Although V/CrCl is useful in retrospective analyses of the
elationship between contrast volume and subsequent renal
njury, the cut point of 3.7 may be a useful tool in
etermining the amount of contrast volume that is likely to
esult in an early abnormal increase in creatinine. Thus,
ultiplying a patient’s estimated CrCl by 3.7 would give an
stimate of the maximum amount of contrast for a given
rocedure, above which the likelihood of developing renal
njury would be concerning.
In summary, we have shown that V/CrCl is a useful and
ndependent predictor of an early increase in postprocedural
erum creatinine in unselected patients undergoing PCI.
his index may be applied prospectively to calculate the
aximum volume of contrast media that can be given
ithout significantly increasing the risk of CAN.
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